At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
BIA 2-093 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase-1, Open-label, Drug Interaction Study Between Eslicarbazepine Acetate 1200 mg and Topiramate 200 mg Following Multiple Dose Administrations in Healthy Male
In Brief
A Phase 1 clinical trial evaluating BIA 2-093 and Topamax for Epilepsy. Completed, enrolled 32 participants.
Detailed Summary
Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpilepsy
Countries--
Collaborators--
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
Primary CompletionFeb 2007
First PostedNov 2014
TodayJul 2026
First PostedNov 5, 2014
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.7 years ago
Interventions
BIA 2-093drug
Topamaxdrug